Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donovan G Kearns

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of the American Academy of Dermatology|August 1, 2020
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemicDonovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
Journal of the American Academy of Dermatology|July 12, 2020
Applying to dermatology residency during the COVID-19 pandemicDonovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
Journal of Drugs in Dermatology : JDD|May 3, 2021
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 PandemicDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
The Journal of Dermatological Treatment|May 28, 2020
Use of systemic therapies for psoriasis in the COVID-19 eraDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Journal of the American Academy of Dermatology|June 14, 2020
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemicDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Journal of the American Academy of Dermatology|October 3, 2020
Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic"Donovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
The Journal of Clinical and Aesthetic Dermatology|November 22, 2021
Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive ReviewDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Lancet (London, England)|January 17, 2021
Abrocitinib for atopic dermatitisShelley K Uppal, Vipawee S Chat, Donovan G Kearns, et al.
Cutis|January 19, 2021
Dermatologists as social media contributors during the COVID-19 pandemicShelley K Uppal, Donovan G Kearns, Vipawee S Chat, et al.
Dermatologic Therapy|May 15, 2021
Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive reviewVipawee S Chat, Shelley K Uppal, Donovan G Kearns, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of the American Academy of Dermatology|August 1, 2020
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemicDonovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
Journal of the American Academy of Dermatology|July 12, 2020
Applying to dermatology residency during the COVID-19 pandemicDonovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
Journal of Drugs in Dermatology : JDD|May 3, 2021
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 PandemicDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
The Journal of Dermatological Treatment|May 28, 2020
Use of systemic therapies for psoriasis in the COVID-19 eraDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Journal of the American Academy of Dermatology|June 14, 2020
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemicDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Journal of the American Academy of Dermatology|October 3, 2020
Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic"Donovan G Kearns, Vipawee S Chat, Shelley Uppal, et al.
The Journal of Clinical and Aesthetic Dermatology|November 22, 2021
Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive ReviewDonovan G Kearns, Shelley Uppal, Vipawee S Chat, et al.
Lancet (London, England)|January 17, 2021
Abrocitinib for atopic dermatitisShelley K Uppal, Vipawee S Chat, Donovan G Kearns, et al.
Cutis|January 19, 2021
Dermatologists as social media contributors during the COVID-19 pandemicShelley K Uppal, Donovan G Kearns, Vipawee S Chat, et al.
Dermatologic Therapy|May 15, 2021
Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive reviewVipawee S Chat, Shelley K Uppal, Donovan G Kearns, et al.
Pageof 3